Midostaurin

Major

Midostaurin Pravastatin Pravachol Increased OATP1B1 substrate exposure Details Midostaurin Ranolazine Aspruzyo Increased ranolazine exposure and an increased CYP3A4 substrate exposure Details Midostaurin Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Midostaurin Repaglinide Prandin® Increased OATP1B1 substrate exposure Details Midostaurin Repotrectinib Augtyro Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Midostaurin Revefenacin Yupelri Increased OATP1B1 substrate exposure Details Midostaurin Ribociclib Kisqali Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Midostaurin Rifampin Rifadin Decreased midostaurin exposure Details Midostaurin Ritlecitinib Litfulo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Midostaurin Ritonavir Norvir Increased midostaurin exposure Details Midostaurin Rosuvastatin Crestor Increased BCRP and OATP1B1 substrate exposure Details Midostaurin Rotavirus Vaccine, Live An increased risk of infection by the live vaccine Details Midostaurin Saquinavir Increased midostaurin exposure Details Midostaurin Selpercatinib Retevmo Increased substrate exposure and an increased risk for adverse effects Details Midostaurin Sevabertinib Hyrnuo Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Midostaurin Sotorasib Lumakras Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Midostaurin St John's Wort Decreased midostaurin exposure Details Midostaurin Sulfasalazine Azulfidine Increased BCRP substrate exposure Details Midostaurin Suzetrigine Journavx Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Midostaurin Taurursodiol Decreased exposure of the CYP3A4 substrate Details Midostaurin Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Midostaurin Telaprevir Increased midostaurin exposure Details Midostaurin Telithromycin Increased midostaurin exposure Details Midostaurin Tenofovir Alafenamide Increased tenofovir alafenamide exposure Details Midostaurin Tocilizumab Actemra Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Midostaurin Topotecan Hycamtin Increased BCRP substrate exposure Details Midostaurin Tovorafenib Ojemda Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Midostaurin Treosulfan Grafapex Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Midostaurin Trofinetide Daybue Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Midostaurin Tucatinib Tukysa Increased exposure to CYP3A substrate and risk of toxicity Details Midostaurin Ubrogepant Ubrelvy Increased BCRP substrate exposure Details Midostaurin Vonoprazan Voquezna Increased CYP3A substrates exposure Details Midostaurin Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Midostaurin Voriconazole Vfend Increased midostaurin exposure Details Midostaurin Voxelotor Oxbryta Increased exposure of sensitive CYP3A4 substrates Details Midostaurin Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details